Compositions and methods for treating mucositis
US-2024415798-A1 · Dec 19, 2024 · US
US12064534B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12064534-B2 |
| Application number | US-202217695964-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 16, 2022 |
| Priority date | Jul 8, 2014 |
| Publication date | Aug 20, 2024 |
| Grant date | Aug 20, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides a novel approach in which zwitterionic networks are used to sequester and deliver ionic biomolecules, such as proteins, without compromising their native conformation and bioactivity. Zwitterionic networks are designed to effectively retain and deliver ionic or polar biomolecules for guided tissue regeneration. The invention represents a conceptual advance and enables a novel strategy for the utilization of zwitterionic motifs as therapeutics delivery vehicles and tissue engineering scaffolds.
Opening claim text (preview).
What is claimed is: 1. An implant consisting of a crosslinked 3-dimensioanl zwitterionic polymer and a protein, wherein the protein is encapsulated in the crosslinked 3-dimensional zwitterionic polymer and is characterized by preserved bioactivity as sequestered, wherein the crosslinked 3-dimensional zwitterionic polymer is polymethacrylate, polyacrylate, polymethacrylamide, or polyacrylamide crosslinked with poly (ethylene glycol) dimethacrylate, poly(ethylene glycol) diacrylate, ethylene glycol diacrylate, or ethylene glycol dimethacrylate. 2. The implant of claim 1 , wherein the protein is a therapeutic osteogenic protein. 3. The implant of claim 1 , wherein the protein is an anabolic agent. 4. The implant of claim 1 , wherein the protein is an angiogenic factor. 5. The implant of claim 1 , wherein the zwitterionic moiety comprises one or more selected from sulfobetaine, phosphorylcholine and carboxybetaine. 6. The implant of claim 5 , wherein the zwitterionic moiety is present in the polymer network as pendant groups to a polymeric backbone. 7. The impant of claim 6 , wherein the zwitterionic moiety is present in the polymer at a density from about 0.05 mol % to about 10 mol %. 8. The implant of claim 1 , wherein the polymer is characterized by a crosslinking density, from about 0.05 mol % to about 10 mol %. 9. The method of claim 1 , wherein the implant is biodegradable. 10. The implant of claim 1 , suitable for implant as a dental implant or bone implant.
for reconstruction of bones; weight-bearing implants · CPC title
Hydrogels or hydrocolloids · CPC title
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds · CPC title
Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title
Macromolecular materials · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.